• Isofol Medical published its annual report for fiscal 2025 on its website, alongside its corporate governance report.
• CEO Petter Segelman Lindqvist said Isofol made progress in 2025 with a focus on resuming clinical development of arfolitixorin.
• He cited positive preliminary interim results reported post year-end.
• He cited ongoing regulatory dialogue.
• He cited expanded work with partner Solasia Pharma.
• He cited a strengthened financial position.
• The report is available at: https://attachment.news.eu.nasdaq.com/a0bdf30d0970ea9fef90a06e61d17a1d5.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Isofol Medical AB published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.